Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy
The primary objective of the study is to assess metabolic plasma markers of insulin resistance in patients with early-stage HER2-negative breast cancers receiving dapagliflozin concomitant with neoadjuvant therapy.
Weekly or dose dense paclitaxel, followed by dose dense doxorubicin plus cycloph... [+18]
Participants who underwent partial excisional biopsy or lumpectomy, segmental ma... [+10]